Kaplan Alan L, Hu Jim C, Morgentaler Abraham, Mulhall John P, Schulman Claude C, Montorsi Francesco
Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Eur Urol. 2016 May;69(5):894-903. doi: 10.1016/j.eururo.2015.12.005. Epub 2015 Dec 21.
The use of testosterone therapy in men with prostate cancer was previously contraindicated, although recent data challenge this axiom. Over the past 2 decades, there has been a dramatic paradigm shift in beliefs, attitude, and treatment of testosterone deficiency in men with prostate cancer.
To summarize and analyze current literature regarding the effect of testosterone replacement in men with prostate cancer.
We conducted a Medline search to identify all publications related to testosterone therapy in both treated and untreated prostate cancer.
The historical notion that increasing testosterone was responsible for prostate cancer growth was based on elegant yet limited studies from the 1940s and anecdotal case reports. Current evidence reveals that high endogenous androgen levels do not increase the risk of a prostate cancer diagnosis. Similarly, testosterone therapy in men with testosterone deficiency does not appear to increase prostate cancer risk or the likelihood of a more aggressive disease at prostate cancer diagnosis. Androgen receptor saturation (the saturation model) appears to account for this phenomenon. Men who received testosterone therapy after treatment for localized prostate cancer do not appear to suffer higher rates of recurrence or worse outcomes; although studies to date are limited. Early reports of men on active surveillance/watchful waiting treated with testosterone have not identified adverse progression events.
An improved understanding of the negative effects of testosterone deficiency on health and health-related quality of life-and the ability of testosterone therapy to mitigate these effects-has triggered a re-evaluation of the role testosterone plays in prostate cancer. An important paradigm shift has occurred within the field, in which testosterone therapy may now be regarded as a viable option for selected men with prostate cancer suffering from testosterone deficiency.
In this article, we review and summarize the existing literature surrounding the use of testosterone therapy in men with prostate cancer. Historically, testosterone was contraindicated in men with a history of prostate cancer. We show that this contraindication is unfounded and, with careful monitoring, its use is safe in that regard.
以前,睾酮疗法对前列腺癌男性患者是禁忌的,不过最近的数据对这一公理提出了挑战。在过去20年里,对于前列腺癌男性患者睾酮缺乏的观念、态度及治疗方面发生了巨大的范式转变。
总结并分析当前关于睾酮替代疗法对前列腺癌男性患者影响的文献。
我们进行了一项医学文献数据库检索,以识别所有与已接受治疗和未接受治疗的前列腺癌患者的睾酮疗法相关的出版物。
过去认为睾酮水平升高会导致前列腺癌生长这一观点,是基于20世纪40年代一些精巧但有限的研究以及轶事病例报告。当前证据表明,内源性雄激素水平高并不会增加前列腺癌诊断风险。同样,睾酮缺乏男性患者接受睾酮疗法似乎也不会增加前列腺癌风险或在前列腺癌诊断时出现更具侵袭性疾病的可能性。雄激素受体饱和(饱和模型)似乎可以解释这一现象。局限性前列腺癌患者接受治疗后再接受睾酮疗法,似乎不会出现更高的复发率或更差的预后;尽管迄今为止的研究有限。早期关于接受睾酮治疗的主动监测/观察等待男性患者的报告未发现不良进展事件。
对睾酮缺乏对健康及与健康相关生活质量的负面影响以及睾酮疗法减轻这些影响的能力有了更好的理解,引发了对睾酮在前列腺癌中所起作用的重新评估。该领域已发生重要的范式转变,其中睾酮疗法现在可能被视为某些患有睾酮缺乏的前列腺癌男性患者的可行选择。
在本文中,我们回顾并总结了有关前列腺癌男性患者使用睾酮疗法的现有文献。从历史上看,有前列腺癌病史的男性患者禁忌使用睾酮。我们表明这种禁忌是没有根据的,并且经过仔细监测,在这方面其使用是安全的。